Blastoid variant of mantle cell lymphoma with lactic acidosis: A case report

被引:12
作者
Ohtsubo, K
Imamura, R
Seki, R
Ohshima, K
Hashiguchi, M
Yakushiji, K
Yoshimoto, K
Ogata, H
Okamura, T
Sata, M
机构
[1] Kurume Univ, Sch Med, Dept Internal Med 2, Kurume, Fukuoka 8300011, Japan
[2] Fukuoka Univ, Sch Med, Dept Pathol, Fukuoka 81401, Japan
关键词
blastoid variant of MCL; Bcl-1/IgH; lactic acidosis; chemotherapy; rituximab;
D O I
10.1532/IJH97.04069
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 20% of mantle cell lymphomas (MCL) present with the blastoid variant associated with poor prognosis. Lactic acidosis complicated with hematologic malignancies is seen infrequently and is associated with a poor outcome. Here we report the case of a patient with the blastoid variant of MCL complicated by lactic acidosis and who achieved complete remission through chemotherapy combined with rituximab therapy. A 77-year-old man presented with peripheral blood lymphoma cells, huge splenomegaly, abdominal and mediastinal lymphadenopathy, and pleural effusion. A bone marrow smear showed an increase in large, abnormal lymphoid cells with oval or round nuclei, distinct nucleoli, and abundant basophilic cytoplasm with vacuolization. Splenic sections also showed massive and diffuse infiltration by these cells. Flow cytometry analysis showed these cells to be positive for CD5, CD19, CD20, and kappa chain and negative for CD10 and CD23. A blastoid variant of MCL was diagnosed from the results of histologic, immunohistochemical (cyclin D1), and cytogenetic (chimeric bcl-1/IgH fusion gene) analyses. The patient recovered from the 2 episodes of severe lactic acidosis for which he had been given chemotherapy, and he achieved complete remission after subsequent chemotherapy combined with rituximab treatment. (C) 2004 The Japanese Society of Hematology.
引用
收藏
页码:428 / 431
页数:4
相关论文
共 23 条
[1]   Mantle cell lymphoma: A clinicopathologic study of 80 cases [J].
Argatoff, LH ;
Connors, JM ;
Klasa, RJ ;
Horsman, DE ;
Gascoyne, RD .
BLOOD, 1997, 89 (06) :2067-2078
[2]   Blastic variant of mantle cell lymphoma:: a rare but highly aggressive subtype [J].
Bernard, M ;
Gressin, R ;
Lefrère, F ;
Drénou, B ;
Branger, B ;
Caulet-Maugendre, S ;
Tass, P ;
Brousse, N ;
Valensi, F ;
Milpied, N ;
Voilat, L ;
Sadoun, A ;
Ghandour, C ;
Hunault, M ;
Leloup, R ;
Mannone, L ;
Hermine, O ;
Lamy, T .
LEUKEMIA, 2001, 15 (11) :1785-1791
[3]   BICARBONATE DOES NOT IMPROVE HEMODYNAMICS IN CRITICALLY ILL PATIENTS WHO HAVE LACTIC-ACIDOSIS - A PROSPECTIVE, CONTROLLED CLINICAL-STUDY [J].
COOPER, DJ ;
WALLEY, KR ;
WIGGS, BR ;
RUSSELL, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (07) :492-498
[4]  
Durig J, 1996, ANN HEMATOL, V72, P97
[5]   European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [J].
Foran, JM ;
Rohatiner, AZS ;
Cunningham, D ;
Popescu, RA ;
Solal-Celigny, P ;
Ghielmini, M ;
Coiffier, B ;
Johnson, PWM ;
Gisselbrecht, C ;
Reyes, F ;
Radford, JA ;
Bessell, EM ;
Souleau, B ;
Benzohra, A ;
Lister, TA .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) :317-324
[6]   STIMULATION OF LACTATE PRODUCTION BY ADMINISTRATION OF BICARBONATE IN A PATIENT WITH A SOLID NEOPLASM AND LACTIC-ACIDOSIS [J].
FRALEY, DS ;
ADLER, S ;
BRUNS, FJ ;
ZETT, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (19) :1100-1102
[7]   Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH [J].
Gutierrez, M ;
Chabner, BA ;
Pearson, D ;
Steinberg, SM ;
Jaffe, ES ;
Cheson, BD ;
Fojo, A ;
Wilson, WH .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) :3633-3642
[8]   Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival [J].
Howard, OM ;
Gribben, JG ;
Neuberg, DS ;
Grossbard, M ;
Poor, C ;
Janicek, MJ ;
Shipp, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1288-1294
[9]  
JAFFE ES, 2001, WHO CLASSIFICATION T, P168
[10]   Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study [J].
Jermann, M ;
Jost, LM ;
Taverna, C ;
Jacky, E ;
Honegger, HP ;
Betticher, DC ;
Egli, F ;
Kroner, T ;
Stahel, RA .
ANNALS OF ONCOLOGY, 2004, 15 (03) :511-516